Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas
Sponsor: National Cancer Institute (NCI)
Listed as NCT00003176, this PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Mar 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Ann Arbor, United States
- • Boston, United States
- • Dallas, United States
- • Houston, United States
- • Los Angeles, United States
- • Madison, United States
- • Pittsburgh, United States
- • San Antonio, United States
- • San Francisco, United States